Dr. Bishal Gyamali discusses results from the AGITG dynamic-III trial presented during the 2025 ASCO Annual Meeting. This was a randomized trial studying ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer.
Link to ecancer discussion
Link to ASCO abstract
